The 2025 BSG/BASL/SAM admission bundle tightens the first 6 hours, adds Doppler ultrasound, and drops routine coagulopathy correction, while AASLD, AGA, EASL, and ACG guidance reshape SBP, HRS-AKI, variceal bleeding, portal vein thrombosis, and alcohol-associated hepatitis

Read the guideline summary and references on AZense.

The 2022 ACC/AHA aortic disease guideline unifies thoracic and abdominal aortic care, lowers surgical thresholds at expert centers, expands genetic testing and family screening, and standardizes acute aortic syndrome management

Read the guideline summary and references on AZense.

The 2023 AHA/ACC chronic coronary disease guideline renames stable ischemic heart disease, elevates SGLT2 inhibitors and GLP-1 therapies, de-escalates routine long-term beta-blockers, and ties revascularization to symptoms rather than ischemia alone

Read the guideline summary and references on AZense.

The first unified AHA/ACC/ADA/ASN guideline defines cardiovascular-kidney-metabolic syndrome, introduces a 0 to 4 staging system, mandates PREVENT-based risk estimation, and places SGLT2 inhibitors and GLP-1 therapies at the center of cardiometabolic care

Read the guideline summary and references on AZense.

The Surgical Infection Society 2024 update is the antimicrobial and antifungal therapy companion to IDSA 2024 Part 1, which covered diagnosis only; it advises against empiric antifungals in lower-risk community-acquired infection and recommends anidulafungin for higher-risk Candida intra-abdominal infection, all anchored on adequate source control

Read the guideline summary and references on AZense.

The IDSA 2024 update on complicated intra-abdominal infections, Part 1, covers risk assessment, diagnostic imaging, and microbiological evaluation only; antimicrobial therapy, source control, and antifungal guidance are reserved for later parts

Read the guideline summary and references on AZense.

The CHEST 2025 companion guideline issues seven conditional recommendations that withhold prophylactic plasma and platelet transfusion in most ICU settings, with lumbar puncture as the one procedure that flips the default

Read the guideline summary and references on AZense.

The CHEST 2024 red cell transfusion guideline makes a restrictive hemoglobin 7 to 8 strategy the strong default across critical illness and GI bleeding, but recommends against a restrictive strategy in acute coronary syndrome

Read the guideline summary and references on AZense.

The 2024 KDIGO CKD guideline gives a tiered SGLT2 inhibitor recommendation, strong for type 2 diabetes with CKD, strong for heavy albuminuria or heart failure regardless of diabetes, and a weaker suggestion for low-albuminuria low-eGFR disease, not a blanket recommendation for all CKD

Read the guideline summary and references on AZense.

The living IDSA guidance retires piperacillin-tazobactam for serious ESBL disease, makes ceftazidime-avibactam standard for KPC-type CRE, prefers sulbactam-durlobactam for CRAB, and requires novel agents for DTR-Pseudomonas

Read the guideline summary and references on AZense.